Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon1 and 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CEBPB, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CEBP Beta also known as CCAAT/enhancer binding protein beta or C/EBPβ is a transcription factor that regulates gene expression in various tissues. It has a molecular mass of approximately 35 kDa. CEBP Beta is expressed in liver adipose tissue and immune cells among others. It binds to DNA at specific CCAAT motifs and regulates transcription of genes involved in immune response metabolism and differentiation.
Biological function summary
CEBP Beta plays important roles in cellular differentiation proliferation and immune function. CEBP Beta is part of the CEBP family of transcription factors which form homo- or hetero-dimers to function effectively often with other family members like CEBP Alpha. Its activity governs important processes in hematopoiesis and adipogenesis. This transcription factor is therefore essential in the regulation of energy homeostasis and immune response influencing the expression of various cytokines and acute-phase proteins.
Pathways
CEBP Beta integrates signals in key biological pathways such as the JAK-STAT and NF-kB pathways. Activation via cytokine signaling CEBP Beta interacts with STAT proteins to modulate gene expression linked to inflammatory responses. It has a significant role in the NF-kB pathway where it cooperates with Rel proteins to regulate genes involved in immune and stress responses including TNF and IL-1.
CEBP Beta is implicated in conditions such as acute myeloid leukemia (AML) and obesity-related complications. Abnormal regulation of CEBP Beta can contribute to leukemogenesis by altering the expression of cell cycle and differentiation genes. Additionally CEBP Beta's role in lipid storage and insulin sensitivity links it to metabolic disorders such as Type 2 diabetes. Interactions with proteins like PPAR gamma in adipose tissues influence these disease processes.
